Access to specially made CAR T-cell therapy for eligible patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial gives people access to a specially made CAR T-cell therapy (a treatment that uses your own immune cells to fight cancer) that didn't pass the usual quality checks but is still considered safe. It's for patients who have no other good options and are already set to receive this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of the approved conditions (like certain lymphomas or leukemias) for which this therapy is already used.
- The treatment dose for you was manufactured but didn't meet the usual quality standards, yet it's still considered safe enough for a clinical trial.
- Your doctor has checked and says you're well enough to receive this treatment.
- Getting new cells collected again (a second leukapheresis) is not possible for you.
- You have no other satisfactory treatment options available, according to your doctor.
- You must not have a history of severe allergic reactions to similar drugs, and no uncontrolled active infection or major inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This study provides access to a CAR T-cell therapy (a treatment that uses your own immune cells to fight cancer) for people with certain types of lymphoma who have no other good treatment options. The therapy is available even though it did not meet commercial standards, but it passed safety checks for this study.
This trial tests whether adding a drug called axatilimab to the standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. CAR-T is a treatment that uses your own immune cells to fight the cancer.
This trial tests whether a type of immunotherapy called axicabtagene ciloleucel (a CAR T-cell therapy) can improve outcomes when given right after initial treatment for high-risk large B-cell lymphoma. It is for people who have not yet started treatment.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.